What does the evidence say about Flaxseed Cardiometabolic Markers Meta-Analysis?

Updated October 2026

Quick Answer

Flaxseed Cardiometabolic Markers Meta-Analysis has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: Unhealthy aging is a growing global concern, characterized by the accelerated decline in physiological and metabolic functions, leading to increased susceptibility to age-related diseases.

Key Takeaways

  • 01Unhealthy aging is a growing global concern, characterized by the accelerated decline in physiological and metabolic functions, leading to increased susceptibility to age-related diseases. [Kunutsor Setor K. (2025)]
  • 02Among these are cardiometabolic diseases, including hypertension, metabolic syndrome (MetS), metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular diseases (CVDs), which collectively represent a significant public health burden. [Kunutsor Setor K. (2025)]
  • 03This condition, characterized by fat accumulation in the liver independent of alcohol consumption, often coexists with obesity, MetS, and T2D, significantly increasing the risk of liver cirrhosis and CVD []. [Kunutsor Setor K. (2025)]
  • 04It is often associated with hormonal imbalance, metabolic disturbances, and reproductive complications, which together contribute to an elevated risk of long-term cardiometabolic disorders. [Singnale P (2026)]
The current Migaku evidence database contains 2 reusable source documents for Flaxseed Cardiometabolic Markers Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Unhealthy aging is a growing global concern, characterized by the accelerated decline in physiological and metabolic functions, leading to increased susceptibility to age-related diseases. [Kunutsor Setor K. (2025); evidence level 3] - Among these are cardiometabolic diseases, including hypertension, metabolic syndrome (MetS), metabolic dysfunction-associated steatotic liver disease (MASLD), type 2 diabetes (T2D), chronic kidney disease (CKD), and cardiovascular diseases (CVDs), which collectively represent a significant public health burden. [Kunutsor Setor K. (2025); evidence level 3] - This condition, characterized by fat accumulation in the liver independent of alcohol consumption, often coexists with obesity, MetS, and T2D, significantly increasing the risk of liver cirrhosis and CVD []. [Kunutsor Setor K. (2025); evidence level 3] - It is often associated with hormonal imbalance, metabolic disturbances, and reproductive complications, which together contribute to an elevated risk of long-term cardiometabolic disorders. [Singnale P (2026); evidence level 4] - To narratively synthesize mechanistic rationale and human clinical evidence on dietary seeds and selected nutraceuticals relevant to PCOS, with emphasis on metabolic and reproductive endpoints of interest to nutrition and obstetrics/gynecology practice. [Singnale P (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Dietary flaxseed: Cardiometabolic benefits and its role in promoting healthy aging
  2. Role of Functional Foods and Nutraceutical Compounds in Alleviating Polycystic Ovary Syndrome: A Narrative Review.